Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus

Dig Dis Sci. 2017 Dec;62(12):3391-3401. doi: 10.1007/s10620-017-4821-6. Epub 2017 Oct 30.

Abstract

Background and aims: Barrett's esophagus, a metaplasia resulting from a long-standing reflux disease, and its progression to esophageal adenocarcinoma (EAC) are characterized by activation of pro-inflammatory pathways, induced by cytokines.

Methods: An in vitro cell culture system representing the sequence of squamous epithelium (EPC1 and EPC2), Barrett's metaplasia (CP-A), dysplasia (CP-B) to EAC (OE33 and OE19) was used to investigate TNF-α-mediated induction of interleukin-8 (IL-8).

Results: IL-6 and IL-8 expressions are increasing with the progression of Barrett's esophagus, with the highest expression of both cytokines in the dysplastic cell line CP-B. IL-8 expression in EAC cells was approx. 4.4-fold (OE33) and eightfold (OE19) higher in EAC cells than in squamous epithelium cells (EPC1 and EPC2). The pro-inflammatory cytokine TNF-α increased IL-8 expression in a time-, concentration-, and stage-specific manner. Furthermore, TNF-α changed the EMT marker profile in OE33 cells by decreasing the epithelial marker E-cadherin and increasing the mesenchymal marker vimentin. The anti-inflammatory compound curcumin was able to repress proliferation and to activate apoptosis in both EAC cell lines.

Conclusion: The increased basal expression levels of IL-8 with the progression of Barrett's esophagus constrain NFκB activation and its contribution in the manifestation of Barrett's esophagus. An anti-inflammatory compound, such as curcumin, could create an anti-inflammatory microenvironment and thus potentially support an increase chemosensitivity in EAC cells.

Keywords: Barrett’s esophagus; EMT; Esophageal adenocarcinoma; Inflammation; TNF-α.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / etiology
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / prevention & control*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Barrett Esophagus / complications
  • Barrett Esophagus / metabolism*
  • Cell Line
  • Curcumin / therapeutic use*
  • Disease Progression
  • Drug Evaluation, Preclinical
  • Epithelial-Mesenchymal Transition
  • Esophageal Neoplasms / etiology
  • Esophageal Neoplasms / metabolism
  • Esophageal Neoplasms / prevention & control*
  • Humans
  • Interleukin-6 / metabolism
  • Interleukin-8 / metabolism*
  • Tumor Necrosis Factor-alpha / metabolism*
  • Vimentin / metabolism

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • IL6 protein, human
  • Interleukin-6
  • Interleukin-8
  • Tumor Necrosis Factor-alpha
  • Vimentin
  • Curcumin